Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066794 · ClinicalTrials.gov registry record · Phase 2
S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
A Phase 2 study of Leukemia, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT00066794: Completed Phase 2 study of Leukemia, sponsored by SWOG Cancer Research Network.
NCT00066794 is a Phase 2 study of Leukemia that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 69 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066794, a Phase 2 study of Leukemia, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cyclosporine, daunorubicin, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving cyclosporine together with daunorubicin and cytarabine works in treating older patients with untreated acute myeloid leukemia.
Conditions Studied
Interventions
- BIOLOGICAL filgrastim
- DRUG cytarabine
- DRUG cyclosporine
- BIOLOGICAL sargramostim
- DRUG daunorubicin hydrochloride
Study Locations (20)
Kansas
- Cancer Center of Kansas, PA - Chanute - Chanute
- Cancer Center of Kansas, PA - Dodge City - Dodge City
- Cancer Center of Kansas, PA - El Dorado - El Dorado
- Cancer Center of Kansas, PA - Kingman - Kingman
- Southwest Medical Center - Liberal
- Cancer Center of Kansas, PA - Newton - Newton
- Cancer Center of Kansas, PA - Parsons - Parsons
- Cancer Center of Kansas, PA - Pratt - Pratt
- Cancer Center of Kansas, PA - Salina - Salina
- Tammy Walker Cancer Center at Salina Regional Health Center - Salina
- Stormont-Vail Cancer Center - Topeka
- St. Francis Comprehensive Cancer Center - Topeka
- Cancer Center of Kansas, PA - Wellington - Wellington
California
- Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center - Orange
- Mercy Regional Cancer Center at Mercy Medical Center - Redding
Illinois
- Saint Anthony's Hospital at Saint Anthony's Health Center - Alton
- Good Samaritan Regional Health Center - Mount Vernon
Alabama
- Mobile Infirmary Medical Center - Mobile
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Idaho
- St. Luke's Mountain States Tumor Institute - Boise - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2004-07 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00066794 record still lists
NCT00066794 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 69 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which filgrastim is the first listed.
NCT00066794 names 20 study sites across 6 states, led by Kansas, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00066794 about?
NCT00066794 is a clinical study titled "S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as cyclosporine, daunorubicin, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving cyclosporin...
What is the current status of trial NCT00066794?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2004-07. Estimated completion is 2010-01.
What conditions does trial NCT00066794 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00066794?
The interventions under investigation include: filgrastim (BIOLOGICAL), cytarabine (DRUG), cyclosporine (DRUG), sargramostim (BIOLOGICAL), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00066794?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00066794 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00066794's enrollment target sits among peer trials
69 90th of 233 higher than 144 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04020575 · 69 participants · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
- NCT04163614 · 69 participants · NA
Blood Pressure Slopes and Ultrafiltration in Hemodialysis Patients
- NCT04164641 · 69 participants · NA
Noraxon myoRESEARCH™ Software Gait Analysis Evaluation and Orthotic Gait Correction in Reducing Diabetic Foot Ulceration Or Subsequent Amputation in Patients With a History of a Diabetic Foot Ulceration
- NCT04493372 · 69 participants · NA
Deciphering Preserved Autonomic Function After Spinal Cord Injury
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia